Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug Guidance

Ribociclib for the adjuvant treatment of HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence

Condition

Breast

Cancer

6 February 2026

-

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Ribociclib 200 mg tablet, in combination with an aromatase inhibitor, for the adjuvant treatment of patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. Maximum treatment duration: 3 years.

Patients with anatomic stage group IIA and node-negative disease must have one additional risk factor:

  • Grade 3 tumour; or

  • Grade 2 tumour and Ki-67 ≥20%; or

  • Grade 2 tumour and high risk by gene signature testing.

Funding status

Ribociclib 200 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.

Clinical indication, subsidy class and MediShield Life claim limit for ribociclib are provided in the Annex.

Guidance_Ribociclib for the adjuvant treatment of HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence (6 Feb 2026)

PES_Ribociclib for adjuvant treatment of HR-positive, HER2-negative early breast cancer (6 Feb 2026)

Back to top